Previous close | 4.6000 |
Open | 4.6000 |
Bid | 4.2000 |
Ask | 6.2000 |
Strike | 1.00 |
Expiry date | 2024-09-20 |
Day's range | 4.6000 - 4.6000 |
Contract range | N/A |
Volume | |
Open interest | 5 |
Helen Thackray, Chief Research & Development Officer of BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), purchased 30,000 shares of the company on May 14, 2024.
On May 13, 2024, Steven Galson, a Director at BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), purchased 21,940 shares of the company, as reported in a recent SEC Filing.
Charles Gayer, Chief Commercial Officer of BioCryst Pharmaceuticals Inc (NASDAQ:BCRX), purchased 30,000 shares of the company on May 13, 2024.